Every DEF 14A that Onconetix, Inc. (ONCO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ONCO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ONCO filings page.
Onconetix, Inc. is asking stockholders to vote on five proposals at its annual meeting on November 10, 2026. They include re-electing Josh Epstein as a Class II director for a term ending at the 2029 annual meeting; approving, under Nasdaq Listing Rule 5635, issuance of up to 154,856,150 shares of Common Stock, subject to adjustment, upon conversion of Series F Preferred Stock issued in a private placement completed July 29, 2026; and authorizing one additional reverse stock split at a ratio from 1-for-2 to 1-for-15, with the Board selecting the ratio. The other proposals concern ratifying MaloneBailey, LLP as independent auditor for fiscal 2026 and adjournment if votes are insufficient.
The proposed split authority would supplement existing authority for additional reverse splits at ratios from 1-for-2 to 1-for-10 before April 30, 2027, subject to an aggregate 1-for-100 limit. Onconetix had 5,241,486 Common Stock shares outstanding as of September 29, 2026, the record date. The Board unanimously recommends voting “FOR” all proposals. Onconetix says that without approval of the Series F proposal, it may be unable to honor conversions at certain adjusted conversion prices.
Onconetix, Inc. is asking stockholders at an April 30, 2026 special meeting to approve authority for one or more reverse stock splits of its common stock at ratios between 1-for-2 and 1-for-10, with all such splits together capped at 1-for-100 and usable for one year.
The aim is to maintain compliance with Nasdaq’s $1.00 minimum bid requirement after prior notices under the Bid Price Rule and Low Priced Stocks Rule, and to support liquidity and future capital-raising. A second proposal would allow adjournment of the meeting to solicit additional proxies. There were 692,927 common shares outstanding as of March 13, 2026.
Onconetix, Inc. called its annual meeting for December 5, 2025 at 10:00 a.m. ET in New York. Holders of Common Stock at the close of business on October 21, 2025 are entitled to vote.
Stockholders will vote on: (1) electing directors (including Thomas Meier and nominee Sarah Romano); (2) the Series D PIPE Proposal; (3) the Series E PIPE Proposal; (4) ratifying the appointment of MaloneBailey as independent auditor; and (5) an adjournment proposal. The Board unanimously recommends voting FOR all items.
The Company states that Nasdaq Rule 5635(a) requires approval because the Series D and Series E preferred and related warrants could result in issuances exceeding 20% of voting power or outstanding shares; conversions or exercises at certain adjusted prices will not occur until stockholder approval. Directors are elected by plurality; other items require a majority of votes cast with a quorum of one-third of eligible Common Stock. There were 1,555,010 shares of Common Stock outstanding as of the record date.